Skip to main content
. Author manuscript; available in PMC: 2013 Mar 29.
Published in final edited form as: J Neuroimmune Pharmacol. 2012 Jun 23;7(3):656–664. doi: 10.1007/s11481-012-9382-z

Fig 2.

Fig 2

The plasma (A) IL-1β and (B) TNF-α levels and their change percentages (%) (C), (D) in patients with schizophrenia after 11 weeks of treatment with risperidone (Risp)+Placebo or Risp+add-on dextromethorphan (DM) (60 mg/day). Plasma samples were collected and analyzed at 0, 2, 4, 8, and 11 weeks. *p < 0.05, **p < 0.01, ***p < 0.001 vs. week 0 data within same group (repeated-measures ANOVA with Newman-Keuls post test).